Servier options rights to up to six Cellectis cancer projects; deal terms amended
Oncology company Cellectis SA granted Servier SA options for exclusive rights to up to six of its preclinical cancer projects, including lead candidate UCART19, an allogenic CD19 T-cell therapy for leukemia.
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.